Looking Past Aduhelm, Biogen Puts Pipeline On Display
Data Expected From Six Trials For Five Drugs Through 2022
In an attempt to show Biogen has more than its troubled Alzheimer’s drug Aduhelm to drive revenue growth, the company’s R&D Day highlighted several programs from its portfolio of 33 clinical-stage assets.
